Tumor heterogeneity and in vitro chemosensitivity testing in ovarian cancer - 10/09/11
Abstract |
OBJECTIVE: Our purpose was to study the heterogeneity of drug response in fresh human ovarian tumors to chemotherapeutic agents in an in vitro chemosensitivity assay.
STUDY DESIGN: This assay evaluates total tumor cell kill by measuring the intracellular adenosine triphosphate levels of untreated controls and drug-exposed cells at various doses after culture for 6 days. The surviving fraction is calculated by dividing the treated values with the control values. One hundred tumors were tested against four single drugs (cisplatin, the active metabolite of cytoxan, 4-hydroxy-peroxy-cyclophosphamide, Taxol, and carboplatin) and two drug combinations (cisplatin plus 4-hydroxy-peroxy-cyclophosphamide; cisplatin plus Taxol).
RESULTS: There is great variation in the degree of cell death for single drugs and drug combinations among the 100 tumors tested.
CONCLUSION: More effective clinical response to chemotherapy may be achieved in patients with ovarian cancer by selecting the most active drugs for chemotherapy, on the basis of in vitro chemosensitivity test results for individual patients. (Am J Obstet Gynecol 1997;176:759-68.)
Le texte complet de cet article est disponible en PDF.Keywords : Human ovarian cancer, chemosensitivity assay, heterogeneity in drug response
Plan
 | From the Division of Gynecologic Oncology, University of Miami. |
| Reprint requests: Bernd-Uwe Sevin, MD, PhD, Mayo Clinic Jacksonville, 4500 San Pablo Road, Jacksonville, FL 32224. |
 | 0002-9378/97 $5.00 + 0 6/6/80058 |
Vol 176 - N° 4
P. 759-768 - avril 1997 Retour au numéro
Article précédent
- Insulin-like growth factor binding protein-1 at the maternal-fetal interface and insulin-like growth factor-I, insulin-like growth factor-II, and insulin-like growth factor binding protein-1 in the circulation of women with severe preeclampsia
- Linda C. Giudice, Natalie A. Martina, Ruth Ann Crystal, Salli Tazuke, Maurice Druzin
- Defining the role of fluorescence in situ hybridization on uncultured amniocytes for prenatal diagnosis of aneuploidies
- Mary E. D'Alton, Fergal D. Malone, David Chelmow, Brian E. Ward, Diana W. Bianchi
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?